

Aleksandra Jotić<sup>1</sup>, Nebojša. M. Lalić<sup>1</sup>, Nadežda Čovičković Šternić<sup>2</sup>, Vladimir Kostić<sup>2</sup>, Katarina Lalić<sup>1</sup>, Tanja Miličić<sup>1</sup>, Milija Mijailović<sup>2</sup>, Ljiljana Lukić<sup>1</sup>, Nataša Rajković<sup>1</sup>, Marija Maćešić<sup>1</sup>, Sandra Aleksić, Jelena Seferović Mitrović<sup>1</sup>, Ljubica Stošić, Miroslava Zamaklar<sup>1</sup>

## ISCHEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES: RELATIONSHIP BETWEEN DECREASED INSULIN SENSITIVITY AND FIBRINOLYSIS IMPAIRMENT

**Abstract:** The role of insulin sensitivity (IS), as well as the association of IS with fibrinolysis impairment, in the occurrence of ischemic stroke, has not been clarified. The study was aimed to analyze IS, plasma insulin (PI) and plasminogen activator inhibitor (PAI)-1 levels in 34 type 2 diabetics (T2D) with ischemic stroke (group A), 30 T2D without ischemic stroke (group B), 33 nondiabetics with ischemic stroke (group C) and 33 healthy controls (group D). Ischemic stroke was confirmed by clinical and neuroimaging criteria. IS levels were determined by the minimal model analysis (Si index). Plasma insulin levels were measured by radioimmunoassay and PAI-1 activity was performed by the plasminogen chromogenic plasmin substrate assay. We found that Si levels were significantly lower in group A vs. B ( $1.17 \pm 0.66$  vs.  $2.79 \pm 0.62$   $\text{min}^{-1}/\text{mU/L} \times 10^4$ ;  $p < 0.001$ ) and in C vs. D ( $3.25 \pm 0.84$  vs.  $6.03 \pm 1.69$   $\text{min}^{-1}/\text{mU/L} \times 10^4$ ;  $p < 0.001$ ), while PI levels were higher in group A vs. B ( $19.46 \pm 4.11$  vs.  $14.79 \pm 1.75$   $\text{mU/L}$ ;  $p < 0.001$ ) and in C vs. D ( $15.16 \pm 2.23$  vs.  $7.54 \pm 2.03$   $\text{mU/L}$ ;  $p < 0.001$ ). Also, PAI-1 activity was significantly higher in group A vs. B ( $7.78 \pm 1.05$  i  $4.56 \pm 0.71$   $\text{mU/L}$ ;  $p < 0.001$ ) and in C vs D ( $4.65 \pm 0.69$  i  $3.48 \pm 1.29$   $\text{mU/L}$ ;  $p < 0.001$ ). Moreover, Si levels correlated with PAI-1, both in T2D and nondiabetics. Our results indicate that appearance of ischemic stroke was associated with decreased insulin sensitivity, together with compensatory

<sup>1</sup> Clinic for endocrinology, diabetes and metabolic diseases, Clinical Center of Serbia, Belgrade

<sup>2</sup> Clinic for neurology, Clinical Center of Serbia, Belgrade, [ajotic@sbb.rs](mailto:ajotic@sbb.rs)

hyperinsulinemia, both in T2D and nondiabetics. Our results imply that impaired insulin sensitivity exerts its atherogenic influence, at least in part, by decreased fibrinolysis.

**Keywords:** ischemic stroke, type 2 diabetes, insulin sensitivity, plasminogen activator inhibitor -1 (PAI-1)

**Sažetak:** Uloga i značaj insulinske senzitivnosti (IS), kao i povezanost IS sa poremećajem fibrinolize za ispoljavanje ishemijskog moždanog udara (IMU) u potpunosti, još uvek nije razjašnjen. Cilj istraživanja je bio da se analiziraju nivoi IS i insulinemije, kao i njihova povezanost sa nivoom plazminogen aktivator inhibitora 1 (PAI-1) u 34 pacijenta sa tipom 2 dijabetesa (T2D) i IMU (grupa A), 30 pacijenata sa T2D bez IMU (grupa B), 33 pacijenta sa IMU bez T2D (grupa C) i 33 zdrave kontrole (grupa D). Postojanje IMU potvrđeno je na osnovu kliničkog i nalaza neurovizuelizacionih procedura. IS je određivana metodom minimalnog modela (Si indeks). Nivo insulina je određen metodom radioimunoeseja, a nivo PAI-1 određivan je hromogenim plazminogen/plazmin substrat esejom. Rezultati su pokazali da su nivoi Si bili značajno niži u grupi A u poređenju sa B ( $1.17 \pm 0.66$  i  $2.79 \pm 0.62 \text{ min}^{-1}/\text{mU/L} \times 10^4$ ;  $p < 0.001$ ), kao i u grupi C u odnosu na D ( $3.25 \pm 0.84$  i  $6.03 \pm 1.69 \text{ min}^{-1}/\text{mU/L} \times 10^4$ ;  $p < 0.001$ ). Grupa A je imala značajno više nivoe insulinemije u poređenju sa grupom B ( $19.46 \pm 4.11$  i  $14.79 \pm 1.75 \text{ mU/L}$ ;  $p < 0.001$ ), kao i grupa C u odnosu na D ( $15.16 \pm 2.23$  i  $7.54 \pm 2.03 \text{ mU/L}$ ;  $p < 0.001$ ). Nivo PAI-1 je bio značajno viši u grupi A u odnosu na B ( $7.78 \pm 1.05$  i  $4.56 \pm 0.71 \text{ mU/L}$ ;  $p < 0.001$ ) i u grupi C u odnosu na D ( $4.65 \pm 0.69$  i  $3.48 \pm 1.29 \text{ mU/L}$ ;  $p < 0.001$ ). Pokazana je korelacija Si sa nivoom PAI-1, u ispitanika sa i bez T2D. Rezultati ukazuju da snižena insulinska senzitivnost, udružena sa kompenzatornom hiperinsulinemijom, može ostvarivati svoj aterogeni uticaj na ispoljavanje IMU i preko sniženja fibrinolize.

**Ključne reči:** ishemijski moždani udar, tip 2 dijabetesa, insulinska senzitivnost, plazminogen aktivator inhibitora -1 (PAI-1)

## Introduction

Decreased insulin sensitivity (IS) plays an important role in the development of atherosclerosis (1), and is recognized risk factor for ischemic stroke (2,3). The mechanisms underlying the association between diminished insulin sensitivity and vascular events are not completely revealed but may involve hyperglycemia (4), dislipidemia, hypertension, hypofibrinolysis and endothelial dysfunction (5). At the

same time, decreased IS, e.g. insulin resistance, is an important pathophysiological mechanism in type 2 diabetes (T2D) (6).

The previous studies suggested that insulin resistance, measured by different metabolic tests, was directly related to different subtypes of ischemic stroke in both T2D patients and nondiabetics (2, 3). Moreover, higher levels of insulin resistance were demonstrated in nondiabetics with both intra and extra cranial atherosclerosis compared to those who had either intra or extra cranial atherosclerosis alone (7).

Hyperinsulinemia, which may be used as a parameter of insulin resistance in nondiabetics, and which is often, although not obligatory, present in patients with T2D as a compensatory response to insulin resistance (8), was also recognized as an independent risk factor for ischemic stroke (9,10).

Also, other relevant atherogenic factors such as hypercoagulability and hypofibrinolysis were related to the insulin resistance (11), and positive relationship between decreased IS and fibrinolysis impairment was demonstrated in patients with T2D and nondiabetics with coronary artery disease (12). However, the association between changes in IS and plasminogen activator inhibitor (PAI)-1 levels, in respect of occurrence of ischemic stroke, has not been elucidated yet.

Therefore, we have explored the relationship between IS and fibrinolysis impairment as the potential mechanism underlying ischemic stroke in T2D patients, as well as in nondiabetics.

## ***Aim***

To analyse the association between insulin sensitivity level and fibrinolysis activity in the occurrence of ischemic stroke in patients with T2D.

## ***Methods***

### ***Patients***

A sixty four patients with T2D were classified into two groups, T2D with (N=34) and without ischemic stroke (N=30), in comparison to nondiabetics with ischemic stroke (N=33) and healthy controls (N=33).

T2D was diagnosed according to the criteria of the World Health Organization (13).

Diagnosis of ischemic stroke was set by neurologist in Institute for Neurology, Clinical Center of Serbia, according to clinical features and brain imaging methods, cranial computerized scan and magnetic resonance imaging, in two consecutive examinations, during the first 7 days from the occurrence of ischemic stroke (14).

The patients with ischemic stroke were included in the study providing that did not show signs of cardioembolic cerebral infarction or coronary heart disease, based on a history of myocardial infarction confirmed either by elevation of serum cardiac enzymes or coronary angiography. T2D patients were treated with oral antidiabetic agents while patients treated with insulin therapy as well as patients who had other endocrine, infectious or malignant disease, were excluded.

All the patients, with or without ischemic stroke, showed the similar level of physical activity. The metabolic evaluation was performed in the Clinic for Endocrinology, Diabetes and Metabolic Diseases, after all the patients were fully informed and gave the informed consent to participate in the study.

### ***Research design***

The interview, containing the questions about medical conditions, current medication and habits, physical examination and metabolic test were conducted in all of the patients included in the study (all completed at the same day). Body weight (BW) and body height (BH) were measured in each subject and used to calculate the body mass index (BMI), according to following formula:

$$\text{BMI (kg/m}^2\text{)} = \text{BM (kg)} / \text{BH}^2 \text{ (m}^2\text{)}$$

Hypertension was diagnosed according to World Health Organization criteria (systolic/diastolic blood pressure  $\geq 140/\geq 90$  mm Hg) or by the use of antihypertensive agents (15).

### ***Metabolic investigation***

The metabolic evaluation was conducted after at least 6 months from occurrence of ischemic stroke and after at least 12h of fasting. Insulin sensitivity was evaluated by frequently sampled intravenous glucose tolerance (FSIGT) test with computerized minimal model analysis to determine the insulin sensitivity index (Si) (16). During this form of FSIGT test, the blood samples for measurement of plasma glucose (PG) and plasma insulin (PI) levels were taken immediately before and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 20, 23, 24, 25, 27, 30, 40, 50, 60, 70, 80, 90, 100, 120, 160 and 180 minutes after stimulation with 0.3g/kg body weight of intravenous glucose. The continuous intravenous infusion of 4mU/kg/min of insulin was administered during 5 minutes, between 20. and 25. minute of test. Si was calculated from the results of PG and PI levels by computerized minimal model analysis, using the MINMOD program (kindly provided by Dr Richard Bergman from the University of Southern California (Los Angeles)).

### ***Laboratory analyses***

PG was measured by glucose oxidase method using a Beckman Glucose Analyser, while PI was determined by radioimmunoassay (INEP-Zemun). Plasma PAI-1 activity was determined by plasminogen chromogenic plasmin substrate assay (Boehringer).

### ***Statistical analyses***

Data are presented as mean  $\pm$  standard error (SE). The continuous variables within each group of patients were analyzed using analysis of variance (ANOVA) with a post hoc Bonferroni test, while the categorical variables were analyzed with  $\chi^2$  test. Differences were considered statistically significant at  $p < 0.05$ . Statistical analysis was performed with the SPSS statistical software package for personal computers.

## ***Results***

### ***Clinical characteristics***

The clinical characteristics of study subjects are shown in Table 1. The age, duration of diabetes, and time period from the onset of ischemic stroke were similar within the groups. All subjects were moderately obese (BMI: A:  $27.56 \pm 3.11$  vs B:  $27.62 \pm 3.70$  vs C:  $26.21 \pm 4.15$  vs D:  $26.34 \pm 2.36$  kg/m<sup>2</sup>,  $p = \text{NS}$ ) and T2D patients showed similar HbA<sub>1c</sub> levels, implying satisfying metabolic control before metabolic investigation. The prevalence of hypertension in patients with ischemic stroke, both diabetics and nondiabetics, was significantly higher comparing to healthy controls, and subjects were matched in respect to the level of systolic and diastolic blood pressure before the metabolic testing was performed.

All T2D patients were treated either with metformin monotherapy or combination of metformin and sulphonilurea agents, patients with hypertension were administered antihypertensive medication (angiotensin-converting enzyme inhibitors, calcium channel blockers, or their combination), while those with ischemic stroke were receiving antiplatelet agents.

Table 1. Clinical characteristics of type 2 diabetic (T2D) patients and nondiabetics with and without ischemic stroke Data are n, means  $\pm$  SE. \* $p < 0.001$  A,B,C vs. healthy controls

	T2D + Ischemic stroke+ A	T2D+ Ischemic stroke- B	Nondiabetics Ischemic stroke+ C	Healthy Controls D
n (M/F)	34 (16/18)	30 (15/15)	33 (16/17)	33 (15/18)
Age (years)	57.01 $\pm$ 2.20	58.10 $\pm$ 2.57	57.63 $\pm$ 2.79	57.87 $\pm$ 2.63
Duration of diabetes (years)	4.82 $\pm$ 1.78	5.84 $\pm$ 2.4	-	-
Duration from onset of ischaemic stroke (years)	1.14 $\pm$ 0.39	-	1.01 $\pm$ 0.21	-
HbA1c (%)	7.35 $\pm$ 0.31*	7.23 $\pm$ 0.24*	5.67 $\pm$ 0.48	4.9 $\pm$ 0.4
Hypertension	22 (64.7%)	19 (63.3%)	19 (57.6%)	5 (15.2%)*
Systolic blood pressure (mm Hg)	152.4 $\pm$ 4.2	154.1 $\pm$ 4.4	151.1 $\pm$ 2.9	135 $\pm$ 3.0*
Diastolic blood pressure (mm Hg)	90.4 $\pm$ 5.7	92.9 $\pm$ 4.9	88.6 $\pm$ 3.1	80 $\pm$ 1.2*
Smoking	13 (38.2%)	11 (36.7%)	12 (36.4%)	10 (30.3%)
Metformin/Metformin+sulph.	6 / 28	8 / 22	-	-
Antiplatelet agents	34 (100%)	30 (100%)	33 (100%)	0 (0%)
Lipid lowering agents	11 (33%)	5 (16.6%)	4 (12.1%)	0 (0%)

### ***Insulin sensitivity***

We found that Si levels were significantly lower in T2D patients with ischemic stroke compared to T2D patients without ischemic stroke (1.17 $\pm$ 0.66 vs. 2.79 $\pm$ 0.62 min<sup>-1</sup>/mU/Lx10<sup>4</sup>;  $p < 0.001$ ). Also, nondiabetics with ischemic stroke showed significantly lower Si levels compared to healthy controls (3.25 $\pm$ 0.84 vs. 6.03 $\pm$ 1.69 min<sup>-1</sup>/mU/Lx10<sup>4</sup>;  $p < 0.001$ ) (Figure 1). The lowest insulin sensitivity level was present in patients with T2D and ischemic stroke.


Si ( $\text{min}^{-1}/\text{mU}/\text{L}\times 10^4$ )

Figure 1. Values are mean  $\pm$  SE. Bar graphs show the values of Si determined by minimal model analysis.

### *Insulin levels*

PI levels were significantly higher in patients with T2D and ischemic stroke compared to T2D patients without ischemic stroke ( $19.46\pm 4.11$  vs.  $14.79\pm 1.75$  mU/L;  $p<0.001$ ) as well as in nondiabetics with ischemic stroke in comparison to healthy controls ( $15.16\pm 2.23$  vs.  $7.54\pm 2.03$  mU/L;  $p<0.001$ ). Also, T2D patients with and without ischemic stroke had higher PI levels than healthy controls ( $p<0.001$ ), while in group with ischemic stroke T2D patients showed significantly higher PI levels compared to nondiabetics ( $p<0.001$ ). On the other hand, T2D patients without ischemic stroke and nondiabetics with ischemic stroke did not significantly differ in respect to PI levels (Figure 2).

Insulin (mU/L)




Figure 2. Values are mean  $\pm$  SE. Bar graphs show the values of basal PI level.

## Fibrinolysis

In the T2D group, PAI-1 levels were significantly higher in patients with ischemic stroke compared to those without ischemic stroke ( $7.78 \pm 1.05$  vs.  $4.56 \pm 0.71$  mU/l;  $p < 0.001$ ), as well as in nondiabetics with ischemic stroke compared to healthy controls ( $4.65 \pm 0.69$  vs.  $3.48 \pm 1.29$  mU/l;  $p < 0.001$ ) (Figure 3). Nevertheless, in the group without ischemic stroke, there was no statistically significant difference in PAI-1 levels between T2D patients and nondiabetics.




Figure 3. Values are mean  $\pm$  SE. Bar graphs show the values of PAI-1 levels.

## Correlations

Our results showed that Si levels correlated with PAI-1 levels both in T2D ( $r = -0.690$ ,  $p < 0.001$ ) and nondiabetic subjects ( $r = -0.437$ ,  $p < 0.001$ ) (Table 2).

T2D	<i>r</i>	<i>p</i>	Nondiabetics	<i>r</i>	<i>p</i>
<i>PAI-1</i>			<i>PAI-1</i>		
Si	-0.690	0.0001	Si	-0.437	0.001

Table 2. Correlation between Si and PAI-1 levels in patients with Type 2 diabetes and nondiabetics



## *Discussion*

Our results showed decreased insulin sensitivity in both T2D patients and non-diabetics with ischemic stroke implying insulin resistance to be an important determinant in development of ischemic stroke. This study provided the evidence that the lowest level of insulin sensitivity is present in T2D patients with ischemic stroke. At the same time, we detected the highest level of fasting insulinemia in T2D patients with ischemic stroke, probably due to the fact that our patients had mostly preserved insulin secretion capacity at the time of metabolic investigation, so hyperinsulinemia reflected the decreased insulin sensitivity level. Compensatory hyperinsulinemia, together with decreased insulin sensitivity levels, was also found in nondiabetics with ischemic stroke, emphasising the role of insulin resistance in pathogenesis of ischemic stroke, which is in agreement with previous study (17).

We decided to measure insulin sensitivity level by using FSIGT with minimal model analysis, due to previously described excellent correlation between this test and hyperinsulinemic euglycemic clamp (18), which is considered to be a “gold standard” for determining insulin sensitivity level, but is significantly more demanding and technically difficult (19).

The association of insulin resistance and different subtypes of ischemic stroke in patients with T2D has been suggested in the previous studies, but by using other metabolic tests to assess insulin sensitivity (the short insulin tolerance test, homeostasis model, immunoreactive insulin after glucose loading in 2h OGTT) than the minimal model method we used (2). Also, the novel study confirmed the existence of insulin resistance in patients with ischemic stroke but without previously documented abnormal glucose tolerance, assessed in the acute phase of ischemic stroke (3).

In order to minimize the previously confirmed harmful effect of «glucose toxicity» to the insulin sensitivity level (20), we selected T2D patients with or without ischemic stroke matched in respect to duration of disease and showing satisfying metabolic control before the evaluation of insulin sensitivity level. Moreover, since age is known to be strongly and independently correlated with the occurrence of ischemic stroke, we selected patients less than 65 years old. Measurements of insulin sensitivity were made after at least 6 months after the stroke, providing sufficient time for investigated patients to approach maximum recovery, showing similar level of physical activity.

The results from Atherosclerosis Risk in Communities (ARIC) Study documented positive correlation between relative risk for ischemic stroke and increased basal insulin levels among nondiabetics, supporting supposed role of insulin resistance in the ischemic stroke pathogenesis (10), which is in agreement with results from the elderly patient population of the Finnish cohort study that included both diabetic and nondiabetic patients (21).

On the other side, a growing body of evidence implicates the important role PAI-1 plays in the development of diabetic macrovascular complications (22). However, the underlying mechanisms in pathogenesis of atherosclerosis, especially in aspect of relationship between decreased insulin sensitivity and fibrinolysis impairment in the onset of ischemic stroke, have not been elucidated yet. Taking into consideration that impaired fibrinolysis is considered to be a possible link between decreased insulin sensitivity and hyperinsulinemia on the one side, and atherosclerosis on the other, we investigated the relationship of insulin sensitivity and PAI-1 levels as an important factor contributing to the pathogenesis of atherosclerosis (23).

Our study demonstrated that T2D patients with ischemic stroke had higher levels of PAI-1, while those with T2D without ischemic stroke did not have significantly different levels of PAI-1 compared to nondiabetics with ischemic stroke. According to some opposite findings that patients with T2D without ischemic stroke had higher PAI-1 levels than nondiabetics (24), our results suggested that further impairment of fibrinolysis does not occur with ischemic stroke in T2D. There were observations that in some ethnic group first relatives of patients with ischemic stroke exhibited increased insulin resistance, hyperinsulinemia and increased PAI-1, implying that impairment in fibrinolysis preceded cerebral infarction (25).

It is possible that abnormalities in the fibrinolytic system may occur even before the onset of ischemic stroke, regarding the increased level of PAI-1 detected in group of T2D diabetics without ischemic stroke, but not significantly different in comparison to nondiabetics with ischemic stroke (12). Novel data emphasized the inherited predisposition of certain genetic susceptibility related to impairments in fibrinolytic activity (26). In addition, we investigated the patients who were not in the acute phase of ischemic stroke in order to clarify the role of increased PAI-1 during the first year after the ischemic stroke. The results imply that the high PAI-1 level in patients with ischemic stroke, both T2D and nondiabetics, represent increased inhibition of fibrinolysis, which was previously reported in nondiabetics up to 2 to 4 years after stroke onset (27).

Obesity is also thought to contribute significantly to elevated plasma PAI-1 levels, taking into consideration the over expression of PAI-1 in adipose tissue (28). Our results demonstrated that Si levels correlated with PAI-1 levels in moderately obese, both T2D and nondiabetic subjects, which is consistent with previous findings that insulin sensitivity was independently related to PAI-1 levels in patients with T2D, as well as in obese subjects with or without T2D (29). Also, the elevated PAI-1 levels were demonstrated already in the early stage of impaired glucose tolerance, implying the relationship between increased PAI-1 activity and risk for T2D, independently of other risk factors, as obesity, insulin resistance, endothelial dysfunction and inflammation (30).

Therefore, insulin resistance might play an important role in the pathogenesis of ischemic stroke, both in T2D patients and nondiabetics.

In conclusion, our results imply that decreased insulin sensitivity, in association with compensatory hyperinsulinemia, might exert atherogenic influence on the occurrence of ischemic stroke, at least in part through impairment of fibrinolysis.

### **References:**

- Beckman JA., Creager MA., Libby P., Diabetes and atherosclerosis: epidemiology, pathophysiology, and management, *JAMA* 2002; 287:2570–2581.
- Matsumoto K., Miyake S., Yano M., Ueki Y., Miyazaki A., Hirao K., Tominaga Y., Insulin Resistance and Classic Risk Factors in Type 2 Diabetic Patients With Different Subtypes of Ischemic Stroke, *Diabetes Care* 1999; 22:1191–1195.
- Urabe T., Watada H., Okuma Y., Tanaka R., Ueno Y., Miyamoto N., Tanaka Y., Hattori N., Kawamori R., Prevalence of Abnormal Glucose Metabolism and Insulin Resistance Among Subtypes of Ischemic Stroke in Japanese Patients, *Stroke* 2009; 40:1289–1295.
- Tanne D., Koren-Morag N., Goldbourt U., Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks, A prospective cohort study, *Stroke* 2004; 35:2351–2355.
- Air EL., Kissela BM., Diabetes, the Metabolic Syndrome, and Ischemic Stroke Epidemiology and possible mechanisms, *Diabetes Care* 2007; 30(12):3131–3140.
- De Fronzo RA., Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis, *J Med* 1997; 50:191–197.
- Park HY., Kyeong-Ho., Park D., Lee HS., Chang H., Kim Y. and Cho KH., Correlation Between Insulin Resistance and Intracranial Atherosclerosis in Patients With Ischemic Stroke Without Diabetes, *Journal of Stroke and Cerebrovascular Diseases* 2008; 17(6):401–405.
- Pratley RE., Weyer C., The role of impaired early insulin secretion in the pathogenesis of type 2 diabetes mellitus, *Diabetologia* 2001; 44:929–945.
- Pyorala M., Miettinen H., Laakso M., Pyorala K., Hyperinsulinemia and the risk of stroke in healthy middle-aged men. The 22 year follow-up results of the Helsinki Policemen Study, *Stroke* 1998; 29:1860–1866.
- Folsom AR., Rasmussen ML., Chambless LE. et al., Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. *Diabetes Care* 1999; 22:1077–1083.
- Potter van Loon BJ., Kluff C., Radder JK., Blankenstein MA., Meinders AE., The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance, *Metabolism* 1993; 42:945–949.
- Festa A., D'Agostino R., Mykkanen L., Tracy RP., Zaccaro DJ., Hales CN., Haffner SM., Relative contribution of Insulin and its precursors fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin resistance Atherosclerosis Study (IRAS), *Arteriosclerosis, Thrombosis and Vascular Biology* 1999; 19:562–568.

- World Health Organization, Definition, Diagnosis, and Classification: Diabetes Mellitus: Report of a WHO Study Group. Geneva, Switzerland: World Health Organization (1985), 9-25. Technical Report Series 727.
- World Health Organization, Proposal for the multinational monitoring of trends and determinants in cardio-vascular disease (MONICA Project). WHO/MNC/82.1 Rev. 1. (1983)
- Chobanian AV., Bakris GL., Black HR., et al., The National High Blood Pressure Education Program Coordinating Committee: Seventh Report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension 2003; 42:1206.
- Pacini G., Bergman RN., Comput Methods Programs Biomed 1986; 23:113–122.
- Shinozaki K., Naritomi H., Shimizu T., Suzuki M., Ikebuchi M., Sawada T., Harano Y., The role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke, Stroke 1996; 27:37–43.
- Saad MF., Anderson RL., Laws A. et al., A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance, Diabetes 1994; 43:1114–1121.
- Howard G., Bergman R., Wagenknecht LE. et al., Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the “minimal model”. Ann Epidemiol 1998; 8:358–369.
- Kissebah AH., Alfarsi S., Evans DJ., Adams PW., Plasma low density lipoprotein transport kinetics in non-insulin dependent diabetes mellitus. J Clin Invest 1983; 71:655–667.
- Kuusisto J., Mykkanen L., Pyorala K., Laakso M., Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects, Stroke 1994; 25:1157–1164.
- Liang X., Kanjanabuch T., Mao SL., Hao CM., Tang YW., Declercq PJ., Hasty AH., Wsberman DH., Fogo AB., and Ma LJ., Plasminogen activator inhibitor-1 modulates adipocyte differentiation, Am J Physiol Endocrinol Metab 2006; 290:E103–E113.
- Vague P., Juhan Vague I., Aillaud MF., Badier C., Viard R., Alessi MC., Collen D., Correlation between blood fibrinolytic activity plasminogen activator inhibitor-1 level, plasma insulin level, and relative body weight in normal and obese subjects, Metabolism 1986; 35:250–253.
- Mansfield MW., Catto AJ., Carter AM., Grant PJ., Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction, Diabet Med 1998 Nov; 15: 953–7.
- Kain K., Catto AJ., Young J., Bamford J., Bavington J., Grant PJ., Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of south Asian patients with ischemic cerebrovascular disease, Stroke 2001; 32:1069.
- Wiklund PG., Nilsson L., Ardnor SN., et al., Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts, Stroke 2005; 36:1661–1665.
- Lindgren A., Lindoff C., Norrving B., Åstedt B., Johansson BB., Tissue plasminogen activator and plasminogen activator inhibitor 1 in stroke patients, Stroke 1996; 27:1066–1071.

- Alessi MC., Peiretti F., Morange P., Henry M., Nalbone G., and Juhan-Vague I., Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease, *Diabetes* 1997; 46:860–867.
- Panahloo A., Mohamed Ali V., Lane A., Green F., Humphries SE., Yudkin JS., Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene, *Diabetes* 1995; 44:37–42.
- Natali A., Toschi E., Baldeweg S., Ciociaro D., Favilla S., Sacca` L., Ferrannini F., Clustering of Insulin Resistance With Vascular Dysfunction and Low-Grade Inflammation in Type 2 Diabetes, *Diabetes* 2006; 55:1133–1140.